108 related articles for article (PubMed ID: 15235928)
1. A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey).
Shibasaki T; Koyama A; Hishida A; Muso E; Osawa G; Yamabe H; Shiiki H; Makino H; Sato H; Ishikawa I; Maeda K; Tomita K; Arakawa M; Ishida M; Sato M; Nagase M; Kashihara N; Yorioka N; Koike T; Saito T; Harada T; Mitarai T; Sugisaki T; Nagasawa T; Tomino Y; Nojima Y; Kobayashi Y; Sakai O
Clin Exp Nephrol; 2004 Jun; 8(2):117-26. PubMed ID: 15235928
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of mizoribine followed by low-dose prednisone in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria.
Matsumoto Y; Shimada Y; Nojima Y; Moriki T
Ren Fail; 2013 Aug; 35(7):936-41. PubMed ID: 23815417
[TBL] [Abstract][Full Text] [Related]
3. Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome.
Saito T; Iwano M; Matsumoto K; Mitarai T; Yokoyama H; Yorioka N; Nishi S; Yoshimura A; Sato H; Ogahara S; Sasatomi Y; Kataoka Y; Ueda S; Koyama A; Maruyama S; Nangaku M; Imai E; Matsuo S; Tomino Y;
Clin Exp Nephrol; 2017 Dec; 21(6):961-970. PubMed ID: 27783276
[TBL] [Abstract][Full Text] [Related]
4. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome.
Yoshioka K; Ohashi Y; Sakai T; Ito H; Yoshikawa N; Nakamura H; Tanizawa T; Wada H; Maki S
Kidney Int; 2000 Jul; 58(1):317-24. PubMed ID: 10886577
[TBL] [Abstract][Full Text] [Related]
5. [Immunosuppressive therapy for nephrotic syndrome and strategy for adverse side effects from that therapy].
Takeda Y; Tomino Y
Nihon Rinsho; 2004 Oct; 62(10):1875-9. PubMed ID: 15500133
[TBL] [Abstract][Full Text] [Related]
6. Positive effects of single-daily high-dose mizoribine therapy after cyclophosphamide in young children with steroid-dependent nephrotic syndrome.
Mizutani A; Fujinaga S; Sakuraya K; Hirano D; Shimizu T
Clin Exp Nephrol; 2019 Feb; 23(2):244-250. PubMed ID: 30121800
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial.
Cattran DC; Appel GB; Hebert LA; Hunsicker LG; Pohl MA; Hoy WE; Maxwell DR; Kunis CL;
Kidney Int; 2001 Apr; 59(4):1484-90. PubMed ID: 11260412
[TBL] [Abstract][Full Text] [Related]
8. Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial).
Hama T; Nakanishi K; Ishikura K; Ito S; Nakamura H; Sako M; Saito-Oba M; Nozu K; Shima Y; Iijima K; Yoshikawa N;
BMC Nephrol; 2018 Sep; 19(1):223. PubMed ID: 30200895
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
Goumenos DS; Katopodis KP; Passadakis P; Vardaki E; Liakopoulos V; Dafnis E; Stefanidis I; Vargemezis V; Vlachojannis JG; Siamopoulos KC
Am J Nephrol; 2007; 27(3):226-31. PubMed ID: 17389782
[TBL] [Abstract][Full Text] [Related]
10. Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome.
Kawasaki Y; Hosoya M; Kobayashi S; Ohara S; Onishi N; Takahashi A; Isome M; Suzuki H
Nephrol Dial Transplant; 2005 Oct; 20(10):2243-7. PubMed ID: 16030039
[TBL] [Abstract][Full Text] [Related]
11. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.
Hofstra JM; Branten AJ; Wirtz JJ; Noordzij TC; du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2010 Jan; 25(1):129-36. PubMed ID: 19666912
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
Choudhry S; Bagga A; Hari P; Sharma S; Kalaivani M; Dinda A
Am J Kidney Dis; 2009 May; 53(5):760-9. PubMed ID: 19268410
[TBL] [Abstract][Full Text] [Related]
13. [Beneficial and adverse effects of high-dosage MZR therapy in the management of children with frequently relapsing nephrotic syndrome].
Goto M; Ikeda M; Hataya H; Ishikura K; Hamasaki Y; Honda M
Nihon Jinzo Gakkai Shi; 2006; 48(4):365-70. PubMed ID: 16780106
[TBL] [Abstract][Full Text] [Related]
14. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.
Goumenos DS; Ahuja M; Davlouros P; El Nahas AM; Brown CB
Clin Nephrol; 2006 May; 65(5):317-23. PubMed ID: 16724651
[TBL] [Abstract][Full Text] [Related]
15. Treatment of membranous nephropathy with mizoribine: A control trial.
Wang X; Song X; Liu Y; Zhang W; An W; Tu Y
Life Sci; 2016 Jun; 154():75-8. PubMed ID: 27079740
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study.
Xie Y; Huang S; Wang L; Miao L; Zhang A; Li Y; Wu X; Wang L; Liu S; Lie C; Chen P; Chen X
Am J Med Sci; 2011 May; 341(5):367-72. PubMed ID: 21293249
[TBL] [Abstract][Full Text] [Related]
17. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.
Bomback AS; Canetta PA; Beck LH; Ayalon R; Radhakrishnan J; Appel GB
Am J Nephrol; 2012; 36(1):58-67. PubMed ID: 22722778
[TBL] [Abstract][Full Text] [Related]
18. Effect of mizoribine pulse therapy in adult membranous nephropathy.
Wang X; Zhang M; Zhang W; Liu Y; Han Y; Chang W
Int Urol Nephrol; 2021 Apr; 53(4):725-731. PubMed ID: 33159256
[TBL] [Abstract][Full Text] [Related]
19. Effect of single-dose oral mizoribine pulse therapy twice per week for frequently relapsing steroid-dependent nephrotic syndrome.
Fujieda M; Ishihara M; Morita T; Hayashi A; Okada S; Ohta T; Sakano T; Wakiguchi H
Clin Nephrol; 2012 Jul; 78(1):40-6. PubMed ID: 22732336
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.
Cattran DC; Appel GB; Hebert LA; Hunsicker LG; Pohl MA; Hoy WE; Maxwell DR; Kunis CL
Kidney Int; 1999 Dec; 56(6):2220-6. PubMed ID: 10594798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
